Read Gene (RDG.WA) Stock Price

Read Gene Price

CLOSED
4.88
​
Market closed

Over the last 17 years Read Gene grew revenue by 40.2% annually, reaching 15.60 M PLN. Earnings per share have grown at 4.0% per year over the last 17 years. For Read Gene, the net margin of 0.6% is broadly stable versus 0.6% a few years ago.

Read Gene stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene business model & stock analysis

Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings.

Frequently asked questions about Read Gene

Converted at the current exchange rate, the Read Gene share trades at 1.11 EUR (4.88 PLN).

The revenue cannot currently be calculated for Read Gene.

The profit cannot currently be calculated for Read Gene.

The P/E ratio cannot be calculated for Read Gene at the moment.

The P/S cannot be calculated for Read Gene currently.

The Eulerpool Quality Score for Read Gene is 5/10.

The ISIN of Read Gene is PLRADGN00014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Read Gene is RDG.WA. The ticker symbol is used to trade Read Gene shares on the stock exchange.

Fair ValueTerminal
4.88 PLN
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Poland
Currency
PLN
Initial public offering
Feb 12, 2009
ISIN
PLRADGN00014
Cusip
X7064F108
Market capitalization
57.54 M PLNMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
172.20
P/B Ratio
18.49
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.85 %
Last updated Nov 7, 2026, 3:45 AM

Read Gene Peer Group

Read Gene FIGI

RDG:PW · BBG000KYH0P6RDGPLN:XS · BBG00PQ1J3G9RDGPLN:XH · BBG00PQ1J3K4RDGPLN:XF · BBG00PQ1J3M2RDGPLN:XD · BBG00PQ1J3N1RDGPLN:XE · BBG00PQ1J3P9RDGPLN:XJ · BBG00PQ1J3Q8RDGPLN:XL · BBG00PQ1J3R7RDGPLN:XG · BBG00PQ1J3S6RDGPLN:XO · BBG00PQ1J3T5RDGPLN:XN · BBG00PQ1J3V2RDGPLN:XA · BBG00PQ1J3Y9